Providence | The Creative Capital

EpiVax is a bioinformatics and vaccine design company dedicated to the development and implementation of computational immunology tools to benefit the biotechnology industry. They recently received a grant for $390,000 from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to optimize delivery of an HIV vaccine.

EpiVax has extensive immunology and microbiology laboratory capabilities including the most sophisticated MHC binding assays on the market. CEO/CSO, Dr. Annie DeGroot, is a pioneer in the field of deimmunizing protein therapeutics and has accumulated several awards recognizing her several medical innovations.